PL373531A1 - Przeciwciało selektywne względem receptora dla liganda indukującego apoptozę spokrewnionego z czynnikiem martwicy nowotworu i jego zastosowania - Google Patents

Przeciwciało selektywne względem receptora dla liganda indukującego apoptozę spokrewnionego z czynnikiem martwicy nowotworu i jego zastosowania

Info

Publication number
PL373531A1
PL373531A1 PL02373531A PL37353102A PL373531A1 PL 373531 A1 PL373531 A1 PL 373531A1 PL 02373531 A PL02373531 A PL 02373531A PL 37353102 A PL37353102 A PL 37353102A PL 373531 A1 PL373531 A1 PL 373531A1
Authority
PL
Poland
Prior art keywords
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
related apoptosis
Prior art date
Application number
PL02373531A
Other languages
English (en)
Other versions
PL211755B1 (pl
Inventor
Tong Zhou
Robert P. Kimberly
William J. Koopman
Albert F. Lobuglio
Donald J. Buchsbaum
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of PL373531A1 publication Critical patent/PL373531A1/pl
Publication of PL211755B1 publication Critical patent/PL211755B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)

Abstract

Przeciwciało według wynalazku wchodzi w reakcję z ludzkim DR5 lub z ludzkim DR4 wytwarzając agonistyczne lub antagonistyczne efekty regulacji ujemnej receptora obejmujące hamowanie proliferacji komórkowej i apoptozy. Ujawniono sekwencje kwasu nukleinowego i sekwencje aminokwasowe przeciwciał DR5 i DR4 oraz wektory i komórki zawierające i eksprymujące te sekwencje były wygenerowane. Opisano szczegółowo sposoby i zastosowania dla tych przeciwciał włączając leczenie związanych z apoptozą chorób i leczenia nieprawidłowego wzrostu komórkowego.
PL373531A 2001-11-01 2002-11-01 Oczyszczone przeciwciało wiążące wybiórczo receptor DR4 dla TRAIL, sposób wybiórczego indukowania apoptozy w komórkach docelowych, sposób hamowania prolifereacji komórek docelowych, kompozycja farmaceutyczna zawierająca przeciwciało, zastosowanie przeciwciała, wyizolowany kwas nukleinowy, wektor, hodowana komórka i oczyszczony polipeptyd PL211755B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34640201P 2001-11-01 2001-11-01

Publications (2)

Publication Number Publication Date
PL373531A1 true PL373531A1 (pl) 2005-09-05
PL211755B1 PL211755B1 (pl) 2012-06-29

Family

ID=23359208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373531A PL211755B1 (pl) 2001-11-01 2002-11-01 Oczyszczone przeciwciało wiążące wybiórczo receptor DR4 dla TRAIL, sposób wybiórczego indukowania apoptozy w komórkach docelowych, sposób hamowania prolifereacji komórek docelowych, kompozycja farmaceutyczna zawierająca przeciwciało, zastosowanie przeciwciała, wyizolowany kwas nukleinowy, wektor, hodowana komórka i oczyszczony polipeptyd

Country Status (19)

Country Link
EP (2) EP2287285A3 (pl)
JP (1) JP4371814B2 (pl)
KR (1) KR101004098B1 (pl)
CN (1) CN100482276C (pl)
AU (1) AU2002350121B2 (pl)
BR (1) BRPI0213844B8 (pl)
CA (1) CA2465040C (pl)
CO (1) CO5580833A2 (pl)
ES (1) ES2357225T3 (pl)
HU (1) HUP0700077A3 (pl)
IL (3) IL161685A0 (pl)
MX (1) MXPA04004185A (pl)
NO (1) NO338458B1 (pl)
NZ (1) NZ532591A (pl)
PL (1) PL211755B1 (pl)
RO (1) RO123115B1 (pl)
RU (1) RU2313537C2 (pl)
WO (1) WO2003037913A2 (pl)
ZA (2) ZA200403116B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
US20040089839A1 (en) 2002-10-25 2004-05-13 Honeywell International, Inc. Fluorinated alkene refrigerant compositions
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
BRPI0706530A2 (pt) * 2006-01-13 2011-03-29 Irm Llc métodos e composições para tratamento de doenças alérgicas
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
CN101611315A (zh) 2006-10-23 2009-12-23 Uab研究基金会 用于对抗癌试剂敏感的癌症的生物标记物及其用途
CN101820913A (zh) * 2007-08-09 2010-09-01 第一三共株式会社 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
RU2405038C1 (ru) * 2009-07-29 2010-11-27 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Способ получения мутантного белка trail человека
US9527915B2 (en) 2009-11-05 2016-12-27 The Uab Research Foundation Treating basal-like genotype cancers
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
JP5918143B2 (ja) 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
HUE068623T2 (hu) * 2011-04-29 2025-01-28 Penn State Res Found Normál és tumorsejtek kismolekulás TRAIL-génindukclója rákellenes terápiaként
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
TWI688572B (zh) 2015-01-26 2020-03-21 美商宏觀基因股份有限公司 包含dr5-結合結構域的多價分子
CA3019692A1 (en) * 2016-04-05 2017-10-12 Universitat Stuttgart Monovalent inhibitor of hutnfr1 interaction
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
US20220221455A1 (en) * 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6250098A (en) * 1997-01-28 1998-08-18 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
IL131328A0 (en) * 1997-02-28 2001-01-28 Boehringer Ingelhem Pharmaceut Self-regulated apoptosis of inflammatory cells by gene therapy
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
EP1178828A4 (en) * 1999-05-06 2004-10-13 Human Genome Sciences Inc RECEPTOR CONTAINING "DEATH DOMAIN"
ES2325305T3 (es) * 1999-05-28 2009-09-01 Genentech, Inc. Anticuerpos dr4 quimericos y usos de los mismos.
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
ES2357225T3 (es) 2011-04-20
JP4371814B2 (ja) 2009-11-25
EP1506011B1 (en) 2015-08-19
EP2287285A2 (en) 2011-02-23
KR101004098B1 (ko) 2011-01-13
PL211755B1 (pl) 2012-06-29
CN100482276C (zh) 2009-04-29
CO5580833A2 (es) 2005-11-30
CN1655814A (zh) 2005-08-17
RO123115B1 (ro) 2010-11-30
IL161685A (en) 2011-03-31
CA2465040C (en) 2013-12-10
EP2287285A3 (en) 2012-05-02
NZ532591A (en) 2008-04-30
NO338458B1 (no) 2016-08-15
BR0213844A (pt) 2006-05-23
KR20040070349A (ko) 2004-08-07
JP2005509414A (ja) 2005-04-14
RU2004116475A (ru) 2005-04-20
EP1506011A2 (en) 2005-02-16
HUP0700077A3 (en) 2012-09-28
IL161685A0 (en) 2004-09-27
BRPI0213844B1 (pt) 2018-12-26
ZA200403116B (en) 2006-06-28
EP1506011A4 (en) 2006-07-12
NO20042269L (no) 2004-06-30
ZA200507050B (en) 2010-03-31
HUP0700077A2 (en) 2007-05-02
CA2465040A1 (en) 2003-05-08
AU2002350121B2 (en) 2007-09-06
RU2313537C2 (ru) 2007-12-27
MXPA04004185A (es) 2005-05-16
BRPI0213844B8 (pt) 2021-05-25
WO2003037913A2 (en) 2003-05-08
WO2003037913A3 (en) 2004-11-18
IL196082A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
PL373531A1 (pl) Przeciwciało selektywne względem receptora dla liganda indukującego apoptozę spokrewnionego z czynnikiem martwicy nowotworu i jego zastosowania
HUP0400951A2 (hu) Egy tumornekrózis faktorral rokon apoptózis indikáló ligandum receptorára specifikus antitest és alkalmazásai
IL161686A0 (en) Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ATE411805T1 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
WO2004063362A3 (en) Cell cycle progression proteins
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
EA201300481A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
DE60334453D1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
PT1087993E (pt) Péptidos fas e anticorpos para modular a apoptose
TW200635946A (en) Binding proteins specific for human matriptase
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
God et al. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47 000 MW acid labile protein in CD4+ T‐cell recognition
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
ATE406094T1 (de) Identifizierung und charakterisierung von genen
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
PT871612E (pt) Isoindolonas fundidas como inibidores de proteina cinase c
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
DE602004032235D1 (de) Dna-vektoren
DK1121439T3 (da) Fremgangsmåder og præparater til inhibering af neoplastisk cellevækst
DK1664307T3 (da) Ny endospermspecifik plantepromotor til afgröder
BR0012301A (pt) Inibidores de crescimento de células epiteliais